| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/JGH.12476 |
| P698 | PubMed publication ID | 24325451 |
| P50 | author | James Fung | Q41791161 |
| Ching-Lung Lai | Q56885069 | ||
| Man-Fung Yuen | Q59187364 | ||
| Ivan Fan Ngai Hung | Q73401116 | ||
| Seto WK | Q79434476 | ||
| Yuk-Fai Lam | Q114725849 | ||
| P2093 | author name string | Danny Ka-Ho Wong | |
| Fung-Yu Huang | |||
| P2860 | cites work | Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy | Q33417353 |
| High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. | Q34391308 | ||
| Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach | Q37074608 | ||
| Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load | Q37346823 | ||
| Acute-on-chronic liver failure in chronic hepatitis B. | Q37958079 | ||
| Future prevention and treatment of chronic hepatitis B infection. | Q38036837 | ||
| Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. | Q39187780 | ||
| Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia | Q39894574 | ||
| Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. | Q42947269 | ||
| Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. | Q43202400 | ||
| Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. | Q43755030 | ||
| High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load | Q44245742 | ||
| A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. | Q44766209 | ||
| Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. | Q45376159 | ||
| Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. | Q45378210 | ||
| Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". | Q50991688 | ||
| Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. | Q51165652 | ||
| Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients | Q57782730 | ||
| Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response | Q58097652 | ||
| Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency | Q58235730 | ||
| Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy | Q58235736 | ||
| Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment | Q58235826 | ||
| Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome | Q58235835 | ||
| Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety | Q58235847 | ||
| Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss | Q58376653 | ||
| Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B | Q58808845 | ||
| P433 | issue | 5 | |
| P921 | main subject | entecavir | Q418586 |
| chronic hepatitis B | Q55779876 | ||
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 1028-1034 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | Journal of Gastroenterology and Hepatology | Q15764401 |
| P1476 | title | Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment | |
| P478 | volume | 29 |
| Q36151658 | Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study |
| Q30391932 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. |
| Q49885455 | Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy |
| Q40324314 | Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B. |
| Q58235686 | Hepatitis B Surface Antigen Seroclearance: Relationship to Hepatitis B e-Antigen Seroclearance and Hepatitis B e-Antigen-Negative Hepatitis |
| Q40272794 | Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B. |
| Q35891425 | Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients |
| Q93080857 | Hepatitis B virus infection in children and adolescents |
| Q39067311 | Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). |
| Q48229827 | Lamivudine: fading into the mists of time. |
| Q59354057 | Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan |
| Q38295855 | Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients? |
| Q35598073 | Oral administered particulate yeast-derived glucan promotes hepatitis B virus clearance in a hydrodynamic injection mouse model |
| Q38928531 | Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection |
| Q46720186 | Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. |
| Q37166945 | The correlation between serum HBsAg levels and viral loads depends upon wild-type and mutated HBV sequences rather than the HBeAg/anti-HBe status |
| Q50087802 | Towards HBV curative therapies |
| Q63740175 | Zika Virus Potentiates the Development of Neurological Defects and Microcephaly: Challenges and Control Strategies |
| Q40769626 | α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare |
Search more.